tetrahydrothiophene-2-carbonyl chloride | 63521-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: tetrahydrothiophene-2-carbonyl chloride
• 英文别名: 2-Chlorocarbonyltetrahydrothiophene；2-tetrahydrothiophenecarboxylic acid chloride；Thiolane-2-carbonyl chloride
• CAS: 63521-95-9
• 化学式: C₅H₇ClOS
• 分子量: 150.629
• InChiKey: GMOYADYGFDLPHE-UHFFFAOYSA-N

物化性质

• 沸点：
  113-114 °C(Press: 25 Torr)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetrahydrothiophene-2-carbonyl chloride 在 tungsten(VI) oxide 吡啶 、 双氧水 作用下， 以 正己烷 为溶剂， 反应 2.83h， 生成 2-(2-Chloroethyl)-1-(tetrahydrothiophen-2-ylcarbonyl)piperidine dioxide
  参考文献：
  名称：

  Spiro Derivatives of Tetrahydrothiophene. Synthesis of the Quinolizidine <3-spiro-2′> tetrahydrothiophene System Using Solid/Liquid or Liquid/Liquid Phase-Transfer Catalysis

  摘要：

  4-氧代八氢喹啉<3-螺-2'>四氢噻吩1',1'-二氧化物可以通过两条独立的途径从2-氰基四氢噻吩合成，两者均使用相转移催化：第一条途径涉及在PTC条件下对2-氰基四氢噻吩进行烷基化，第二条途径则是使用2-氯乙基哌啶与2-氯羰基四氢噻吩进行N-酰化，最后在PTC条件下进行环烷基化。得到两个螺旋化合物的立体异构体。

  DOI：

  10.1055/s-1987-33430
• 作为产物：
  描述：

  2-氰基四氢噻吩 在 盐酸 、 氯化亚砜 作用下， 生成 tetrahydrothiophene-2-carbonyl chloride
  参考文献：
  名称：

  Spiro Derivatives of Tetrahydrothiophene. Synthesis of the Quinolizidine <3-spiro-2′> tetrahydrothiophene System Using Solid/Liquid or Liquid/Liquid Phase-Transfer Catalysis

  摘要：

  4-氧代八氢喹啉<3-螺-2'>四氢噻吩1',1'-二氧化物可以通过两条独立的途径从2-氰基四氢噻吩合成，两者均使用相转移催化：第一条途径涉及在PTC条件下对2-氰基四氢噻吩进行烷基化，第二条途径则是使用2-氯乙基哌啶与2-氯羰基四氢噻吩进行N-酰化，最后在PTC条件下进行环烷基化。得到两个螺旋化合物的立体异构体。

  DOI：

  10.1055/s-1987-33430

文献信息

• NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20140296254A1

  公开（公告）日：2014-10-02

  Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

  描述了符合一般式(I)的二取代3,4-二氨基-3-环丁烯-1,2-二酮化合物。还描述了包括这些化合物的药物组合物以及使用这些化合物和组合物治疗趋化因子介导的疾病的方法。
• 5-Fluorouracil derivatives, and their pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04349552A1

  公开（公告）日：1982-09-14

  A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.

  一种化合物的化学式为：##STR1##其中R是从诺伯尼尔、诺伯烯基、双环[2,2,2]-庚基和金刚烷基中选择的桥环脂环基，可选择地被来自较低烷基、羧基、较低烷氧羰基、烷基二氧基、N,N-双(较低)烷基氨基甲酰、氨基、较低烷氧羰胺基和卤素的至少一种取代基取代。该化合物可用于治疗人类和动物的癌症。
• Process for the preparation of optically active carboxylic acids and
  申请人：Consortium fur Elektrochemische Industrie GmbH

  公开号：US05334730A1

  公开（公告）日：1994-08-02

  The present invention provides a process for the preparation of optically active carboxylic acids of the formula I* or II* ##STR1## in which X is an oxygen or sulfur atom and n is 1 or 2. The process comprises reacting a racemic carboxylic acid I or II or its derivatives with an optically active 2-amino-carboxylic acid ester to give the diastereomeric carboxylic acid amides, separating the diastereomers and, after cleavage of the amide bond, isolating the optically active carboxylic acids of the general formula I* or II*. The invention also provides certain novel optically active carboxylic acid amides and a tetrahydrothiopyran-2-carboxylic acid.

  本发明提供了一种制备式I*或II*的光学活性羧酸的方法##STR1##其中X是氧或硫原子，n为1或2。该方法包括将外消旋羧酸I或II或其衍生物与光学活性的2-氨基羧酸酯反应，得到反二对映异构的羧酸酰胺，分离反二对映体，并在酰胺键裂解后，分离出通式I*或II*的光学活性羧酸。该发明还提供了一些新颖的光学活性羧酸酰胺和四氢噻吩-2-羧酸。
• Fangchinoline derivatives induce cell cycle arrest and apoptosis in human leukemia cell lines via suppression of the PI3K/AKT and MAPK signaling pathway
  作者：Jin Yang、Shengcao Hu、Chunlin Wang、Junrong Song、Chao Chen、Yanhua Fan、Yaacov Ben-David、Weidong Pan

  DOI：10.1016/j.ejmech.2019.111898

  日期：2020.1

  Fangchinoline, a bisbenzylisoquinoline alkaloid extracted from Stephania tetrandra S. Moore, is known to exert anti-cancer activity. A series of new fangchinoline derivatives have been synthesized and evaluated for their anti-cancer activity. In cell viability assay, these fangchinoline derivatives displayed higher proliferation inhibitory activity on leukemia and breast cancer cell lines than the

  防己胆碱是从Stephania tetrandra S. Moore提取的双苄基异喹啉生物碱，具有抗癌活性。已经合成了一系列新的防己诺林碱衍生物，并对其抗癌活性进行了评估。在细胞活力测定中，这些防己诺林碱衍生物对白血病和乳腺癌细胞系的抑制增殖活性高于亲本化合物。其中，3e通过诱导G0 / G1细胞周期停滞和凋亡而对白血病细胞HEL表现出最强的细胞生长抑制活性，呈剂量和时间依赖性。用3e处理HEL细胞还导致MAPK和PI3K / AKT途径的显着抑制以及c-MYC下调，这可能是诱导凋亡和细胞周期停滞的原因。在对接分析中，3e和Akt1之间的高亲和力相互作用是该化合物抑制激酶的主要原因。该衍生物化合物可用作治疗白血病的有效抗癌剂。
• 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010941A1

  公开（公告）日：1980-05-14

  The present invention provides compounds of the general formula:- wherein R is an optionally substituted bridged alicyclic radical or a substituted lower alkyl radical, the substituent being an optionally substituted bridged alicyclic group, an amino, protected amino, lower alkoxy, acyl, lower alkylthio, cyano(lower)alkylthio, arylthio or optionally substituted heterocyclic radical or a carboxy and esterified carboxy group, with the proviso, that when the substituent is a carboxy or esterified carboxy group then the lower alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted or substituted lower alkenyl radical, the substituent being an optionally substituted bridged alicyclic group, an optionally substituted aryl radical or an optionally substituted heterocyclic radical; or a halophenyl radical; or an optionally substituted heterocyclic radical. 'The present invention also provides processes for the preparation of these compounds and pharmaceutical composition containing them. Furthermore, the present invention is concerned with a method of treating cancer which comprises administering these compounds to mammals suffering from cancer.

  本发明提供通式为：- 的化合物。 其中 R 是任选取代的桥式脂环基或取代的低级烷基，取代基是任选取代的桥式脂环基、氨基、保护氨基、低级烷氧基、酰基、低级烷硫基、氰基（低级）烷硫基、芳硫基或任选取代的杂环基或羧基和酯化羧基，但条件是当取代基是羧基或酯化羧基时，低级烷基含有 3 至 6 个碳原子；或未取代或取代的低级烯基，取代基为任选取代的桥式脂环基、任选取代的芳基或任选取代的杂环基；或卤代苯基；或任选取代的杂环基。 '本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺。此外，本发明还涉及一种治疗癌症的方法，该方法包括对患有癌症的哺乳动物施用这些化合物。